MedTrace Logo

Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms (AAA) Metabolic Activity

NCT01253252 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-07-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether Positron Emission Tomography imaging can help to predict the evolutivity of AAA treated with endovascular prosthesis.

Conditions

  • Abdominal Aortic Aneurysm

Interventions

RADIATION

[18F] Fluorodeoxyglucose PET Scan Imaging

Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis. The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake. The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations.

RADIATION

CT scan

Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.

BIOLOGICAL

Blood sampling for biological investigations

A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Patrick ROSSIGNOL, MD, phD · Nancy's Hospital, Plurithematic Clinical Investigation Centre

  • Jean-Baptiste MICHEL, MD, PhD · Institut National de la Santé Et de la Recherche Médicale (INSERM) U698 FRANCE

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253252 on ClinicalTrials.gov